IDE-397 is a small molecule commercialized by Ideaya Biosciences, with a leading Phase II program in Gastric Cancer and Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of IDE-397’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for IDE-397 is expected to reach an annual total of $69 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

IDE-397 Overview

IDE397 is under development for the treatment of solid tumor, non-small cell lung cancer, pancreatic cancer, adenoid cystic carcinoma (ACC), thymic cancer, colorectal cancer, esophageal, gastric, bladder, head and neck cancer. They act by targeting MAT2A (methionine adenosyltransferase 2A) in tumor cells having MTAP gene deletion. The drug candidates are developed based on synthetic lethality drug discovery platform. It is administered through oral route.

Ideaya Biosciences Overview

Ideaya Biosciences (Ideaya) is a precision medicine company which develops oncology therapeutics. The company’s lead product candidate IDE196, a protein kinase C (PKC) inhibitor, targets cancers with GNAQ and GNA11 mutations. It develops small molecule inhibitors based on synthetic lethality against known and novel targets. Ideaya also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). The company collaborates with Novartis Institute for Biomedical Research, Pfizer Inc, Boston Children’s Hospital, Cancer Research UK and, other academic and research institutes for cancer biology, immunology, and small molecule drug discovery. Ideaya is headquartered in South San Francisco, California, the US.

The company reported revenues of (US Dollars) US$27.9 million for the fiscal year ended December 2021 (FY2021), an increase of 43% over FY2020. The operating loss of the company was US$50.3 million in FY2021, compared to an operating loss of US$35.3 million in FY2020. The net loss of the company was US$49.8 million in FY2021, compared to a net loss of US$34.5 million in FY2020. The company reported revenues of US$29.7 million for the third quarter ended September 2022, compared to a revenue of US$5.9 million the previous quarter.

For a complete picture of IDE-397’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.